Last Update 26 Jun 26
Fair value Decreased 8.19%OBDC: Lower Yields And Credit Headwinds Will Test Income Thesis
Analysts have trimmed their average price target on Blue Owl Capital to about $13.31 from $14.50, citing updated models that factor in lower interest yields, softer investment activity, and some credit quality pressure across the broader business development company group.
Analyst Commentary
Recent research on Blue Owl Capital highlights a more tempered stance from Wall Street, with price targets adjusted to reflect lower interest yields, softer deployment of capital, and some pressure on credit quality across the broader business development company group.
Bullish Takeaways
- Bullish analysts still see valuation support for Blue Owl Capital, even after price target cuts, arguing that current levels already factor in more cautious assumptions on yields and activity.
- They point out that, despite some credit headwinds across the group, credit quality is described as largely in check, which they view as sufficient for the current portfolio to support the existing investment case.
- Positive commentary around the broader group indicates that, for investors focused on income and diversified exposure to private credit, Blue Owl Capital may still fit within a long term allocation framework.
- Model updates that reduce price targets are viewed by bullish analysts as a recalibration of expectations rather than a thesis break, with execution on capital deployment and credit monitoring remaining the key drivers to watch.
Bearish Takeaways
- Bearish analysts focus on lower interest yields feeding into revised earnings models, which compresses implied upside and can limit re rating potential for Blue Owl Capital in the near term.
- Softer investment activity raises questions about the pace at which the company can grow its portfolio, which in turn affects fee and interest income assumptions in analyst models.
- Commentary on worsening credit quality across the business development company group keeps some investors cautious, as any further deterioration could pressure net asset values and returns if not contained.
- Expectations for continued redemptions from direct lending retail evergreen funds lead bearish analysts to frame the sector, including Blue Owl Capital, as more likely to tread water rather than deliver strong re rating in the short term.
What’s in the News for Blue Owl Capital
- Blue Owl Capital completed a share repurchase tranche, buying back 3,143,108 shares for US$35.20 million between February 17, 2026 and March 31, 2026, under the previously announced buyback program. Source: Key Developments
- The company announced a quarterly dividend of US$0.3100 per share, payable on July 15, 2026, with an ex date and record date of June 30, 2026. Source: Key Developments
- A Reuters report noted that a Blue Owl adviser was sued by an investor over alleged inflating of fund values. Source: Reuters, Periodicals
- Bloomberg reported that Blue Owl Capital tendered less than 1% of shares into an offer. Source: Bloomberg, Periodicals
Valuation Changes for Blue Owl Capital
- Fair Value: Trimmed from $14.50 to $13.31, indicating a modest reset in the modeled price level for Blue Owl Capital.
- Discount Rate: Lowered slightly from 11.80% to about 11.07%, reflecting an updated assessment of required return in the valuation work.
- Revenue Growth: Shifted from a projected increase of about 1.15% to a decline of about 5.78%, pointing to more cautious assumptions for dollar revenue trends.
- Net Profit Margin: Adjusted higher from roughly 46.79% to about 53.65%, implying a view that dollar earnings may remain relatively resilient even on softer dollar revenue expectations.
- Future P/E: Reduced from about 11.91x to roughly 10.35x, suggesting a lower valuation multiple being used in updated models.
Catalysts
About Blue Owl Capital
Blue Owl Capital focuses on direct lending solutions to larger, recession resilient private companies, targeting consistent income and capital preservation for shareholders.
What are the underlying business or industry changes driving this perspective?
- Scaling through the merger with OBDC II and prior portfolio combinations is increasing diversification and operating leverage. This should enhance net investment income and support ROE accretion as fixed costs are spread over a larger asset base.
- The structural shift of larger private companies and sponsors toward direct lending solutions, even alongside fully open syndicated markets, is sustaining robust deal flow and fee income. This is supporting long term revenue growth.
- Emphasis on senior secured lending to larger, noncyclical borrowers in areas like health care, technology and business services is improving portfolio stability. This should help protect net margins and limit future credit losses.
- Ability to commit larger holds in bigger tranches as average deal sizes rise is expanding Blue Owl’s role as lead lender on high quality transactions. This can support higher asset yields, upfront fees and ultimately earnings power.
- Development of joint ventures and strategic credit vehicles in asset based and alternative credit is creating incremental, noncorrelated income streams. These can offset lower base rates and support sustainable dividends and net investment income.
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Blue Owl Capital's revenue will decrease by 5.8% annually over the next 3 years.
- Analysts assume that profit margins will increase from 20.2% today to 53.6% in 3 years time.
- Analysts expect earnings to reach $800.3 million (and earnings per share of $1.29) by about June 2029, up from $360.4 million today.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 10.4x on those 2029 earnings, down from 14.7x today. This future PE is lower than the current PE for the US Capital Markets industry at 39.7x.
- Analysts expect the number of shares outstanding to decline by 2.88% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 11.07%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?
- A prolonged decline in base rates from recent peak levels toward the 3% SOFR implied by the forward curve would pressure asset yields on Blue Owl Capital's predominantly floating rate portfolio. This would reduce net investment income, compress ROE and likely require a reset of the dividend to a lower level, which could weigh on the share price through lower earnings.
- Persistent spread tightening in both syndicated and direct lending markets, with single B issuers already clearing at historically tight levels, limits the ability to reprice risk appropriately and may lock in lower coupon structures on new originations. This would reduce future revenue growth and net margins as legacy higher yielding loans roll off.
- Secular growth in deal size and the concentration of very large tranches in upper middle market borrowers increases single name exposure and refinancing risk. Any turn in the credit cycle or sector specific shock could lead to larger individual impairments, higher nonaccruals and write downs that erode NAV and depress earnings.
- Tariff and trade policy shifts that persistently raise input costs for portfolio companies reliant on imports from China, as seen with Conair and Beauty Industry Group, highlight vulnerability to geopolitical and supply chain shocks that could spread to other borrowers. This could drive higher credit losses, lower fair value marks and weaker net asset value progression over time.
- Shareholder and market skepticism about private credit risks, combined with Blue Owl Capital's stock trading materially below NAV despite stable credit metrics, may persist if headlines overpower fundamentals. This could constrain the company’s ability to issue equity at attractive levels, limit growth in fee earning assets and dampen total return through a structurally lower valuation multiple on earnings.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $13.31 for Blue Owl Capital based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $15.0, and the most bearish reporting a price target of just $11.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.5 billion, earnings will come to $800.3 million, and it would be trading on a PE ratio of 10.4x, assuming you use a discount rate of 11.1%.
- Given the current share price of $10.68, the analyst price target of $13.31 is 19.8% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Blue Owl Capital?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.